Evidence map›Paper›PMID 40552830›Full record

ArticleJournal of virology2025

The role of Nef in the long-term persistence of the replication-competent HIV reservoir in South African women.

Sherazaan D Ismail, Shorok Sebaa, Bianca Abrahams, Martha C Nason, Mitchell J Mumby, Jimmy D Dikeakos, Sarah B Joseph, Matthew Moeser, Ronald Swanstrom, Nigel Garrett and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sherazaan D IsmailInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-8098-9829
Shorok SebaaInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Bianca AbrahamsInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Mitchell J MumbyDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Jimmy D DikeakosDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.ORCID 0000-0001-8141-5395
Sarah B JosephDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Matthew MoeserLineberger Comprehensive Cancer Centre, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ronald SwanstromDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7777-0773
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Carolyn WilliamsonInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Thomas C QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Melissa-Rose Abrahams *Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-1907-4929
Andrew D Redd *Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-4651-1423

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Characterizing intact proviral HIV-1 reservoir size and determinants of reservoir dynamics in African populationsU01AI152151 · NIAID · UNIVERSITY OF CAPE TOWN · PI ABRAHAMS, MELISSA-ROSE · 2020 to 2024
$914k
CIHR 186284National Research Foundation 129659NIAID NIH HHS P30 AI036214NIAID NIH HHS U01 AI152151NIH HHS 1U01AI152151-01
6 · The paper itself

Abstract

HIV-1 Nef mediates immune evasion and viral pathogenesis in part through the downregulation of cell surface cluster of differentiation 4 (CD4) and major histocompatibility complex class I (MHC-I) on infected cells. While the Nef function of circulating viral populations found early in infection has been associated with reservoir size in early-treated cohorts, there is limited research on how its activity impacts reservoir size in people initiating treatment during chronic infection. In addition, there is little research on its role in the persistence of viral variants during long-term antiretroviral therapy (ART). Phylogenetically distinct

Indexed as

HIV-1HIV Infectionsnef Gene Products, Human Immunodeficiency VirusVirus ReplicationAdultCD4 AntigensCD4-Positive T-LymphocytesDisease ReservoirsFemaleHistocompatibility Antigens Class IHumansSouth AfricaViral LoadCD4 AntigensHistocompatibility Antigens Class Inef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1HIV latencyHIV reservoirhost-pathogen interactionshost-virus interactionmajor histocompatibility complexMHC-INef

Identifiers

PMID40552830
PMCPMC12282088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.